Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Meanwhile, some big employers are adding ...

The drugs identified for negotiation in the second round include: Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic ... REUTERS / Reuters Another potential headwind is Medicare drug pricing negotiations. The earnings report is ...

The approval for Wegovy opened the door for Part D coverage, as Medicare is forbidden from covering weight-loss drugs otherwise. This year marks the first plan year that Wegovy will be covered by ...